FOLH1 and posterior cortical atrophy: Based on the results of the VISION trial, 177Lu-vipivotide tetraxetan (Pluvicto®) was approved by the FDA and EMA in 2022 for the treatment of PSMA-positive metastatic castration-resistant PCa.